SCHEMBL4386839

SCHEMBL4386839

Cc1cc(-n2c(C)cc(OCc3cccc(F)c3F)c(Br)c2=O)ccc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.56
MRGPRX4 Q96LA9 2/20 0.51
PTGER1 P34995 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384803 0.90 MAPK14 (0.62) MAPK14PTGER1
SCHEMBL4381253 0.87 MAPK14 (0.73) MAPK14
SCHEMBL4390686 0.82 MRGPRX4 (0.48) MRGPRX4PTGER1
SCHEMBL4386844 0.78 MAPK14 (0.41) MAPK14PTGER1
SCHEMBL6505467 0.77 MAPK14 (0.78) MAPK14
SCHEMBL4379423 0.76 MAPK14 (0.84) MAPK14
SCHEMBL4384433 0.76 MAPK14 (0.86) MAPK14
SCHEMBL29595052 0.76 MAPK14 (0.86) MAPK14
SCHEMBL4386846 0.75 NOTUM (0.42) MAPK14PTGER1
SCHEMBL4376140 0.75 MAPK14 (0.82) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885MRGPRX4 889/4885PTGER1 170/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885MRGPRX4 693/4885PTGER1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.